Results 91 to 100 of about 4,565 (213)

Adverse Event Signals Associated with Beta-Lactamase Inhibitors: Disproportionality Analysis of USFDA Adverse Event Reporting System

Journal of Xenobiotics
Background: Beta-lactamase inhibitors (BLIs) are widely used with beta-lactam antibiotics to combat resistant infections, yet their safety profiles, especially for newer agents, remain underexplored.
Kannan Sridharan, Gowri Sivaramakrishnan
doaj   +1 more source

Fighting Antimicrobial Resistance: Innovative Drugs in Antibacterial Research

Angewandte Chemie International Edition, Volume 64, Issue 10, March 3, 2025.
This article provides an overview over antibacterial drugs investigated in the past three decades. Aspects of the compound's origins, their cellular targets, the antibacterial spectrum and proof‐of‐concept in animal studies are covered and current trends are highlighted.
Roderich D. Süssmuth, Marcel Kulike‐Koczula, Peng Gao, Simone Kosol   +3 more
wiley   +1 more source

Infections Management in the Lung Transplant Setting in Italy: A Web‐Survey

Transplant Infectious Disease, Volume 27, Issue 2, March/April 2025.
A web survey has revealed significant variation in infection management practices across Italian lung transplant centers. These differences encompass key aspects of infection prevention and control, including antibiotic protocols and cytomegalovirus prophylaxis, underscoring a lack of consistency in fundamental strategies.
Andrea Lombardi, Paolo Grossi, Malgorzata Mikulska, Maddalena Giannella, Renato Pascale, Serena Marinello, Francesca Montagnani, Elena Seminari, Silvia Corcione, Alessandra Bandera, Alessandro Bertani, Alessandra Mularoni, for the Infection Prevention and Treatment Working Group of the LUNG‐SITO study group   +12 more
wiley   +1 more source

Treatment of Bloodstream Infections Due to Gram-Negative Bacteria with Difficult-to-Treat Resistance [PDF]

, 2020
The rising incidence of bloodstream infections (BSI) due to Gram-negative bacteria (GNB) with difficult-to-treat resistance (DTR) has been recognized as a global emergency. The aim of this review is to provide a comprehensive assessment of the mechanisms
Bassetti, Matteo, Giacobbe, Daniele Roberto, Peghin, Maddalena, Sepulcri, Chiara, Vena, Antonio   +4 more
core   +1 more source

Diversity of resistance mechanisms in carbapenem-resistant Enterobacteriaceae at a health care system in Northern California, from 2013 to 2016 [PDF]

, 2019
The mechanism of resistance in carbapenem-resistant Enterobacteriaceae (CRE) has therapeutic implications. We comprehensively characterized emerging mechanisms of resistance in CRE between 2013 and 2016 at a health system in Northern California.
Andermann, Tessa, Banaei, Niaz, Bhatt, Ami, Budvytiene, Indre, Gaur, Rajiv L., Gomez, Carlos A., Kültz, Dietmar, Sandlund, Johanna, Senchyna, Fiona, Shi, Gongyi, Tamburini, Fiona B., Tenover, Fred C., Tickler, Isabella A., Tremintin, Guillaume, Truong, Cynthia, Watz, Nancy   +15 more
core   +1 more source

Meropenem/Vaborbactam in Pediatrics: 2 Cases of CRE Intraabdominal Infection. [PDF]

J Pediatr Pharmacol Ther
Meropenem/vaborbactam is a combination antibiotic with a carbapenem and a carbapenemase inhibitor typically reserved for extensively drug-resistant bacterial infections, such as carbapenem-resistant Enterobacterales (CRE). Meropenem/vaborbactam is approved by the United States Food and Drug Administration for use in adults for complicated urinary tract
Sano U, Meyers R, Hasan U, Smoke S.
europepmc   +2 more sources

Spotlight commentary: Treatment of multidrug‐resistant Gram‐negative infections in the era of growing antimicrobial resistance

British Journal of Clinical Pharmacology, Volume 91, Issue 9, Page 2485-2489, September 2025.
Luka Bielen, Andro Vujević, Luka Csenar
wiley   +1 more source

Simultaneous post-neurosurgical ventriculitis and bacteraemia by two different strains of KPC-producing K. pneumoniae successfully treated with meropenem/vaborbactam and high dose of fosfomycin

Journal of Global Antimicrobial Resistance
Objective: A case of post-neurosurgical ventriculitis caused by a KPC-producing Klebsiella pneumoniae (KPC-Kp) with a ceftazidime/avibactam-resistant, meropenem-susceptible phenotype is reported.
Lorenzo Volpicelli, Sara Cairoli, Dania Al Ismail, Floriana Baisi, Federica Sacco, Bianca Maria Goffredo, Mario Venditti, Alessandra Oliva   +7 more
doaj   +1 more source

Clin Infect Dis [PDF]

The dramatic increase in the prevalence and clinical impact of infections caused by bacteria producing carbapenemases is a global health concern.

core  

Multicenter clinical evaluation of Etest meropenem-vaborbactam (bioMérieux) for susceptibility testing of Enterobacterales (Enterobacteriaceae) and Pseudomonas aeruginosa [PDF]

, 2019
Meropenem-vaborbactam (MEV) is a novel carbapenem-beta-lactamase inhibitor combination antibiotic approved by the U.S. Food and Drug Administration (FDA) for treatment of complicated urinary tract infections, including pyelonephritis, in adults.
Anglade, Claire, Bridon, Laurence, Burnham, Carey-Ann D, Davies, Leanne, Garner, Omai B, Garrett, Sheri, Jean, Sophonie, Richards, Jennifer, Wallace, Meghan, Wootton, Mandy   +9 more
core   +1 more source